Freeze-and-Immune combo takes on tough liver cancer
NCT ID NCT06710223
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. Doctors will freeze part of the tumor (cryoablation) and deliver an immune-boosting drug directly into the liver's blood supply. After that, participants receive two immunotherapy drugs every four weeks. The main goal is to see if this combination is safe and tolerable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SD-101 (nelitolimod), durvalumab, tremelimumab, and cryoablation
What this could lead to
If successful, this could point toward a new combination treatment that helps control advanced liver cancer.
What could go wrong
This is a very early phase 1 trial with only 20 people, so it is primarily checking safety. The treatment may not shrink tumors or improve survival, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego
RECRUITINGSan Diego, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••